CA3222575A1 - Methods of treating nerve agent-induced seizures - Google Patents

Methods of treating nerve agent-induced seizures Download PDF

Info

Publication number
CA3222575A1
CA3222575A1 CA3222575A CA3222575A CA3222575A1 CA 3222575 A1 CA3222575 A1 CA 3222575A1 CA 3222575 A CA3222575 A CA 3222575A CA 3222575 A CA3222575 A CA 3222575A CA 3222575 A1 CA3222575 A1 CA 3222575A1
Authority
CA
Canada
Prior art keywords
tezampanel
benzodiazepine
hours
pharmaceutically acceptable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3222575A
Other languages
English (en)
French (fr)
Inventor
Christopher Francis Toombs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proniras Corp
Original Assignee
Proniras Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proniras Corp filed Critical Proniras Corp
Publication of CA3222575A1 publication Critical patent/CA3222575A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3222575A 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures Pending CA3222575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208885P 2021-06-09 2021-06-09
US63/208,885 2021-06-09
PCT/US2022/032783 WO2022261287A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Publications (1)

Publication Number Publication Date
CA3222575A1 true CA3222575A1 (en) 2022-12-15

Family

ID=84425551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3222575A Pending CA3222575A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Country Status (10)

Country Link
US (1) US20240277696A1 (enExample)
EP (1) EP4352047A4 (enExample)
JP (1) JP2024521430A (enExample)
KR (1) KR20240022544A (enExample)
CN (1) CN117836284A (enExample)
AU (1) AU2022291138A1 (enExample)
CA (1) CA3222575A1 (enExample)
IL (1) IL309097A (enExample)
MX (1) MX2023014418A (enExample)
WO (1) WO2022261287A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511741B1 (en) * 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US11045462B2 (en) * 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2018169798A1 (en) * 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
IL309097A (en) 2024-02-01
WO2022261287A1 (en) 2022-12-15
JP2024521430A (ja) 2024-05-31
KR20240022544A (ko) 2024-02-20
MX2023014418A (es) 2024-02-13
CN117836284A (zh) 2024-04-05
EP4352047A4 (en) 2025-04-16
EP4352047A1 (en) 2024-04-17
US20240277696A1 (en) 2024-08-22
AU2022291138A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
EP2459565B1 (en) Saxitoxin derivatives, methods and compositions for studying, imaging, and treating pain
EP3828174A1 (en) Pyridazinone derivative
JP2019528259A (ja) スピロ−ラクタムｎｍｄａ受容体修飾因子およびその使用
EP3390392B1 (en) Alkyl dihydroquinoline sulfonamide compounds
US10633399B2 (en) Functionalized aminobenzoboroxoles
CN118265710A (zh) 吡啶化合物作为kv7.2增强剂
EP3390393A1 (en) Alkynyl dihydroquinoline sulfonamide compounds
TW202308634A (zh) 使用sGC刺激劑之CNS疾病治療
JP5466510B2 (ja) シドノンイミン−特異的ドーパミン再摂取阻害剤およびそのドーパミン関連障害の治療における使用
US20240277696A1 (en) Methods of treating nerve agent-induced seizures
US9468620B2 (en) Methods of treating ototoxicity
KR20180119590A (ko) 감염 치료용 조성물 및 방법
AU2014237569B2 (en) Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
US8168632B2 (en) Bicyclic amide derivatives for the treatment of respiratory disorders
US20130109660A1 (en) Novel pyrimidinecarboxamide derivatives
TW202345831A (zh) Ｋｉｔ激酶抑制劑及其使用方法
CN118829626A (zh) 新颖双环戊烷衍生物
ES2405055T3 (es) Agonistas muscarínicos
MXPA03010506A (es) Derivados de dihidromid-azo(5,1-a)-beta-carbolina, un metodo para su preparacion y su aplicacion como un farmaco.
WO2021216781A1 (en) Afmt analogs and their use in methods of treating parkinson's disease
EP2678337A1 (en) 2-amino-naphthyridine derivatives
KR20210084592A (ko) Rho 키나아제 억제제, 이를 제조하기 위한 방법 및 이의 용도
NZ753451A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
NZ753453B2 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK1142596A (en) 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250529

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250529